In our in vivo experiments, the iMSC secretome more effectively reduced the expression levels of key AD biomarkers (IL‐4, IL‐13, IL‐31, IL‐22, CCL17, CCL22, and TSLP) and other inflammatory cytokines (IFN‐γ, TNF‐α, IL‐1β, and IL‐6) in lesional skin compared to 0.03% Tacrolimus. This evidence concerns the gene CCL22 and Alzheimer disease.